Drug Overview
Humira (adalimumab; AbbVie/Eisai) is a recombinant human immunoglobulin G1 monoclonal antibody that acts as a tumor necrosis factor (TNF) inhibitor. In the US and EU, Humira is marketed by AbbVie, while in Japan, Abbott partnered with Eisai in 1999 to commercialize and develop the biologic.
Humira is approved for use in several autoimmune indications, namely rheumatoid arthritis, psoriatic arthritis, axial Spondyloarthritis, Behçet’s syndrome, ulcerative colitis, juvenile idiopathic arthritis, Crohn’s disease, hidradenitis suppurativa, non-infectious uveitis, and plaque psoriasis
Humira (adalimumab; AbbVie/Eisai) is a recombinant human immunoglobulin G1 monoclonal antibody that acts as a tumor necrosis factor (TNF) inhibitor. In the US and EU, Humira is marketed by AbbVie, while in Japan, Abbott partnered with Eisai in 1999 to commercialize and develop the biologic.
Humira is approved for use in several autoimmune indications, namely rheumatoid arthritis, psoriatic arthritis, axial Spondyloarthritis, Behçet’s syndrome, ulcerative colitis, juvenile idiopathic arthritis, Crohn’s disease, hidradenitis suppurativa, non-infectious uveitis, and plaque psoriasis
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES